Enzon Pharmaceuticals Inc (ENZN) Insider Acquires $228,149.52 in Stock

Enzon Pharmaceuticals Inc (OTCMKTS:ENZN) insider Family Fund Couchman purchased 950,623 shares of the business’s stock in a transaction on Monday, January 7th. The stock was purchased at an average cost of $0.24 per share, for a total transaction of $228,149.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

OTCMKTS ENZN opened at $0.26 on Friday. Enzon Pharmaceuticals Inc has a 12-month low of $0.20 and a 12-month high of $0.30.

ILLEGAL ACTIVITY NOTICE: “Enzon Pharmaceuticals Inc (ENZN) Insider Acquires $228,149.52 in Stock” was originally published by WKRB News and is the property of of WKRB News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.wkrb13.com/2019/01/11/enzon-pharmaceuticals-inc-enzn-insider-acquires-228149-52-in-stock.html.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron for use in the treatment of chronic hepatitis C; and Sylatron for use in the treatment of melanoma disease. The company was founded in 1981 and is headquartered in Cranford, New Jersey.

Featured Story: Cost of Equity For A Business, Investors

Receive News & Ratings for Enzon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply